Antibody Drug Discovery

10.1142/p743 ◽  
2011 ◽  
Author(s):  
Clive R Wood
Keyword(s):  
Antibodies ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 12 ◽  
Author(s):  
Jordan Graves ◽  
Jacob Byerly ◽  
Eduardo Priego ◽  
Naren Makkapati ◽  
S. Vince Parish ◽  
...  

Driven by its successes across domains such as computer vision and natural language processing, deep learning has recently entered the field of biology by aiding in cellular image classification, finding genomic connections, and advancing drug discovery. In drug discovery and protein engineering, a major goal is to design a molecule that will perform a useful function as a therapeutic drug. Typically, the focus has been on small molecules, but new approaches have been developed to apply these same principles of deep learning to biologics, such as antibodies. Here we give a brief background of deep learning as it applies to antibody drug development, and an in-depth explanation of several deep learning algorithms that have been proposed to solve aspects of both protein design in general, and antibody design in particular.


Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 178
Author(s):  
Kazuya Nagano ◽  
Yasuo Tsutsumi

Antibody drugs with a high affinity and specificity are effective and safe for intractable diseases, such as cancers and autoimmune diseases. Furthermore, they have played a central role in drug discovery, currently accounting for eight of the top 20 pharmaceutical products worldwide by sales. Forty years ago, clinical trials on antibody drugs that were thought to be a magic bullet failed, partly due to the immunogenicity of monoclonal antibodies produced in mice. The recent breakthrough in antibody drugs is largely because of the contribution of phage display technology. Here, we reviewed the importance of phage display technology as a powerful platform for antibody drug discovery from various perspectives, such as the development of human monoclonal antibodies, affinity enhancement of monoclonal antibodies, and the identification of therapeutic targets for antibody drugs.


2020 ◽  
Author(s):  
Yi Yang ◽  
Zhihong Li ◽  
Yu Zhu ◽  
Jingshu Xie ◽  
Yunyun Chen

2017 ◽  
Vol 22 (7) ◽  
pp. 7_73-7_77
Author(s):  
Hiroki SHIRAI

2005 ◽  
Vol 5 (1) ◽  
pp. 125-135 ◽  
Author(s):  
Maria AT Groves ◽  
Jane K Osbourn

Sign in / Sign up

Export Citation Format

Share Document